Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc (PCSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results GlobeNewswire - Wed Oct 30, 3:15PM CDT

PCSA : 0.9002 (-1.08%)
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts BayStreet.ca - Tue Oct 15, 8:31AM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in...

ONCY : 0.9927 (-0.58%)
PCSA : 0.9002 (-1.08%)
JAGX : 0.9613 (-1.90%)
BCTX : 0.7516 (+24.79%)
ONC.TO : 1.38 (-1.43%)
RHHBY : 35.2880 (+0.45%)
Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST Globe Newswire - Fri Aug 5, 2022

HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...

PCSA : 0.9002 (-1.08%)
Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 Globe Newswire - Thu Aug 4, 2022

HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage...

PCSA : 0.9002 (-1.08%)
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 Globe Newswire - Wed Aug 3, 2022

HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage...

PCSA : 0.9002 (-1.08%)
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022 Globe Newswire - Tue Jul 12, 2022

HANOVER, MD., July 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage...

PCSA : 0.9002 (-1.08%)
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Thu May 12, 2022

Amended Next Generation Capecitabine study has restarted which will elucidate timelines for de novo formation of DPDExpanded efforts for enrollment in...

PCSA : 0.9002 (-1.08%)
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine) Globe Newswire - Wed Apr 20, 2022

Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The...

PCSA : 0.9002 (-1.08%)
Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis Globe Newswire - Tue Apr 5, 2022

Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >$1B marketExpect top line...

PCSA : 0.9002 (-1.08%)
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update Globe Newswire - Wed Mar 30, 2022

Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the...

PCSA : 0.9002 (-1.08%)

Barchart Exclusives

1 EV Stock Under $10 With 25% Upside Potential Barchart - 1 hour ago
This charging stock has been under heavy pressure lately amid concerns over the fate of EV tax credits. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot